申请人:Neurogen Corporation, A Corporation of the State of Delaware
公开号:US20030181455A1
公开(公告)日:2003-09-25
Disclosed are compounds of the formula:
1
and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X
1
, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABA
A
receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABA
A
receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.
Disclosed are compounds of the formula:
and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X
1
, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABA
A
receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABA
A
receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.
Disclosed are compounds of the formula:
and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X
1
, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABA
A
receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABA
A
receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.
The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.